EUVIMEDEUVIMED entdecken
Open Access

Relugolix in Clinical Practice: The Best Route for All?

Lisa M Cordes iD, Fatima Karzai, William D Figg, Ravi A Madan

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Lisa M Cordes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Androgen deprivation therapy (ADT) has been a mainstay of prostate cancer treatment for decades. Relugolix was FDA-approved in 2020 and is currently the only ADT option via an oral route. While the opportunity to use an oral medication for this indication has some advantages, a balanced discussion is required to understand in what clinical settings this agent truly has benefit over long-acting injectable formulations of ADT. Furthermore, patient preference, compliance, financial toxicity, and perhaps most importantly, pharmacologic characteristics must be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleHumansAndrogen AntagonistsPyrimidinonesPhenylurea Compounds

Substanzen

relugolixAndrogen AntagonistsPyrimidinonesPhenylurea Compounds

Autor:innen und Institutionen

  • Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • Office of Clinical Research, National Institutes of Health, Bethesda, MD, USA.

ORCID-Profile: Lisa M Cordes

Zitieren

APA

Cordes, L. M., Karzai, F., Figg, W. D., & Madan, R. A. (2023). Relugolix in Clinical Practice: The Best Route for All?. The Oncologist. https://doi.org/10.1093/oncolo/oyad099

Vancouver

Cordes LM, Karzai F, Figg WD, Madan RA. Relugolix in Clinical Practice: The Best Route for All?. The Oncologist. 2023. doi:10.1093/oncolo/oyad099

BibTeX
@article{Cordes2023,
  author = {Cordes, Lisa M and Karzai, Fatima and Figg, William D and Madan, Ravi A},
  title = {Relugolix in Clinical Practice: The Best Route for All?},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad099}
}
Kostenlos starten →